Enterprise Bank & Trust Co acquired a new stake in shares of Amarin Co. plc (NASDAQ:AMRN) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 35,324 shares of the biopharmaceutical company’s stock, valued at approximately $733,000.
Several other institutional investors also recently added to or reduced their stakes in the company. venBio Select Advisor LLC increased its position in Amarin by 37.8% in the fourth quarter. venBio Select Advisor LLC now owns 5,575,000 shares of the biopharmaceutical company’s stock worth $75,876,000 after purchasing an additional 1,530,000 shares during the last quarter. Perceptive Advisors LLC increased its position in Amarin by 699.0% in the fourth quarter. Perceptive Advisors LLC now owns 4,875,600 shares of the biopharmaceutical company’s stock worth $64,553,000 after purchasing an additional 4,265,400 shares during the last quarter. Clearbridge Investments LLC increased its position in Amarin by 704,126.6% in the third quarter. Clearbridge Investments LLC now owns 3,704,232 shares of the biopharmaceutical company’s stock worth $60,268,000 after purchasing an additional 3,703,706 shares during the last quarter. BlackRock Inc. increased its position in Amarin by 0.3% in the third quarter. BlackRock Inc. now owns 3,403,454 shares of the biopharmaceutical company’s stock worth $55,374,000 after purchasing an additional 11,024 shares during the last quarter. Finally, Eversept Partners LP increased its position in Amarin by 26.9% in the fourth quarter. Eversept Partners LP now owns 1,263,407 shares of the biopharmaceutical company’s stock worth $17,195,000 after purchasing an additional 267,707 shares during the last quarter. Hedge funds and other institutional investors own 48.32% of the company’s stock.
Several equities research analysts recently weighed in on AMRN shares. BidaskClub cut shares of Amarin from a “buy” rating to a “hold” rating in a research report on Thursday, March 21st. Zacks Investment Research lowered shares of Amarin from a “hold” rating to a “sell” rating in a research note on Tuesday, January 15th. SunTrust Banks reaffirmed a “buy” rating on shares of Amarin in a research note on Monday, January 7th. Citigroup dropped their price objective on shares of Amarin to $20.00 in a research note on Tuesday, January 8th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Amarin in a research note on Monday, April 1st. Three research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Amarin currently has an average rating of “Buy” and a consensus target price of $32.17.
NASDAQ AMRN traded up $0.24 on Wednesday, hitting $18.63. 207,350 shares of the stock were exchanged, compared to its average volume of 8,106,181. The company has a quick ratio of 2.04, a current ratio of 2.40 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $5.89 billion, a price-to-earnings ratio of -47.49 and a beta of 1.27. Amarin Co. plc has a 52-week low of $2.35 and a 52-week high of $23.33.
Amarin (NASDAQ:AMRN) last posted its quarterly earnings data on Wednesday, February 27th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.03). The business had revenue of $77.30 million for the quarter, compared to the consensus estimate of $73.87 million. The firm’s revenue for the quarter was up 43.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.08) earnings per share. Equities research analysts anticipate that Amarin Co. plc will post -0.19 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This piece was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.com-unik.info/2019/04/24/enterprise-bank-trust-co-acquires-shares-of-35324-amarin-co-plc-amrn.html.
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Further Reading: What are benefits of a growth and income fund?
Want to see what other hedge funds are holding AMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amarin Co. plc (NASDAQ:AMRN).
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.